Glazer Capital, LLC Inozyme Pharma, Inc. Put Options Transaction History
Glazer Capital, LLC
- $2.8 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding INZY
# of Institutions
83Shares Held
48.6MCall Options Held
162KPut Options Held
0-
Beryl Capital Management LLC Redondo Beach, CA6.32MShares$25.3 Million3.83% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million16.98% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million1.16% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I03.2MShares$12.8 Million0.5% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...